Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the perugia multidisciplinary team for thoracic tumors

Tumori

Volumn 94, Issue 3, 2008, Pages 398-405

  Ludovini, Vienna ^a   Pistola, Lorenza ^a   Gregorc, Vanesa ^b   Floriani, Irene ^c   Rulli, Eliana ^c   Di Carlo, Luciana ^a   Semeraro, Antonia ^a   Daddi, Giuliano ^a   Darwish, Samir ^a   Stocchi, Lucia ^a   Tofanetti, Francesca Romana ^a   Bellezza, Guido ^d   Sidoni, Angelo ^d   Tognellini, Rita ^a   Crinò, Lucio ^a   Tonato, Maurizio ^a  

^a Azienda Ospedaliera   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Bd 2; DNA ploidy; HER 2; Ki67; Non small cell lung cancer; p53; Prognosis; S phase fraction

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53;

ADENOCARCINOMA; ADULT; AGED; ANEUPLOIDY; APOPTOSIS; ARTICLE; ASPIRATION BIOPSY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CIGARETTE SMOKING; DISEASE FREE SURVIVAL; DNA DETERMINATION; ELECTROCORTICOGRAPHY; FEMALE; FLOW CYTOMETRY; HISTOGRAM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PLOIDY; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; THORAX TUMOR; UNIVARIATE ANALYSIS;

EID: 48249087719     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160809400317     Document Type: Article

References (31)

1. Cox G, Jones JL, Andi A, Waller DA, O'Byrne KJ: A biological staging model for operable non-small cell lung cancer. Thorax, 56: 561-566, 2001.
2. D'Amico TA, Massey M, Herndon JE 2nd, Moore MB, Har-pole DH Jr: A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg, 117: 736-743, 1999.
3. Tanaka F, Yanagihara K, Otake Y, Yamada T, Shoji T, Miyahara R, Inui K, Wada H: Prognostic factors in patients with resected pathologic (p-) T1-2N1M0 non-small cell lung cancer (NSCLC). Eur J Cardiothorac Surg, 19: 555-561, 2001.
4. Pastorino U, Andreola S, Tagliabue E, Pezzella F, Incarbone M, Sozzi G, Buyse M, Menard S, Pierotti M, Rilke F: Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol, 15: 2858-2865, 1997.
5. Cagini L, Monacelli M, Giustozzi G, Moggl L, Bellezza G, Sidoni A, Bucciarelli E, Darwish S, Ludovini V, Pistola L, Gregorc V, Tonato M: Biological prognostic factors for early stage completely resected non-small cell lung cancer. J Surg Oncol, 74: 53-60, 2000.
6. Mountain CF: Revisions in the international system for staging lung cancer. Chest, 111: 1710-1717, 1997.
7. Beasley MB, Brambilla E, Travis WD: The 2004 World Health Organization classification of lung tumors. Semin Roentgenol, 40: 90-97, 2005.
8. Zajicek J: Sampling of cells from human tumours by aspiration biopsy for diagnosis and research. Eur J Cancer, 1: 253-258, 1965.
9. Scagliotti GV, Micela M, Gubetta L, Leonardo E, Cappia S, Borasio P, Pozzi E: Prognostic signiflcance of Ki67 labelling in resected non small cell lung cancer. Eur J Cancer, 29A: 363-365, 1993.
10. Dean PN, Jett JH: Mathematical analysis of DNA distributions derived from flow microfluorometry. J Cell Biol, 60: 523-528, 1974.
11. Bozzetti C, Franciosi V, Crafa P, Carbognani P, Rusca M, Nizzoli R, Guazzi A, Naldi N, Cocconi G: Biological variables in non-small cell lung cancer: comparison between immuno-cytochemical determination on fine needle aspirates from surgical specimens and immunohistochemical determination on tissue sections. Lung Cancer, 29: 33-41, 2000.
12. Harpole DH Jr, Herndon JE 2nd, Wolfe WG, Inglehart JD, Marks JR: A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res, 55: 51-56, 1995.
13. Hilbe W, Dirnhofer S, Oberwasserlechner F, Eisterer W, Ammann K, Schmid T, Hilbe G, Thaler J, Woll E: Immunohistochemical typing of non-small cell lung cancer on cryostat sections: correlation with clinical parameters and prognosis. J Clin Pathol, 56: 736-741, 2003.
14. Pence JC, Kerns BJ, Dodge KD, Iglehart JD: Prognostic significance of the proliferation index in surgically resected non-small cell lung cancer. Arch Surg, 128: 1382-1390, 1993.
15. Simony J, Pujol JL, Radal M, Ursule E, Michel FB, Pujol H: In situ evaluation of growth fraction determined by monoclonal antibody Ki-67 and ploidy in surgically resected non-small cell lung cancers. Cancer Res, 50: 4382-4387, 1990.
16. Zimmerman PV, Hawson GA, Bint MH, Parsons PG: Ploidy as a prognostic determinant in surgically treated lung cancer. Lancet, 2: 530-533, 1987.
17. Dazzi H, Thatcher N, Hasleton PS, Swindell R: DNA analysis by flow cytometry in nonsmall cell lung cancer: relationship to epidermal growth factor receptor, histology, tumour stage and survival. Respir Med, 84: 217-223, 1990.
18. Isobe H, Miyamoto H, Shimizu T, Haneda H, Hashimoto M, Inoue K, Mizuno S, Kawakami Y: Prognostic and therapeutic significance of the flow cytometric nuclear DNA content in non-small cell lung cancer. Cancer, 65: 1391-1395, 1990.
19. Carey FA, Gray E, Salto-Tellez M, Kelly C, Dye R, Duvall E, Lamb D: Interobserver variation in cell selection for DNA image cytometry. J Clin Pathol, 48: 616-619, 1995.
20. Rom WN, Hay JG, Lee TC, Jiang Y, Tchou-Wong KM: Molecular and genetic aspects of lung cancer. Am J Respir Crit Care Med, 161: 355-367, 2000.
21. Silvestrini R, Costa A, Lequaglie C, Mochen C, Veneroni S, Leutner M, Ravasi G: Bcl-2 protein and prognosis in patients with potentially curable non-small-cell lung cancer. Virchows Arch, 432: 441-444, 1998.
22. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, Harris A, Gatter KC, Mason DY: Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med, 329: 690-694, 1993.
23. Borner MM, Brousset P, Pfanner-Meyer B, Bacchi M, Von-lanthen S, Hotz MA, Altermatt HJ, Schlaifer D, Reed JC, Betticher DC: Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer. Br J Cancer, 79: 952-958, 1999.
24. Fleming MV, Guinee DG Jr, Chu WS, Freedman AN, Caporaso NE, BennettWP, Colby TV, Tazelaar H, Abbondanzo SL, Jett J, Pairolero P, TrastekV, Liotta LA, Harris CC, Travis WD: Bcl-2 immunohistochemistry in a surgical series of non-small cell lung cancer patients. Hum Pathol, 29: 60-64, 1998.
25. Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti CA, Basolo F, Bevilacqua G: Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br J Cancer, 71: 1003-1007, 1995.
26. SoiniY, Paakko P, Lehto VP: Histopathological evaluation of apoptosis in cancer. Am J Pathol, 153: 1041-53, 1998.
27. Hockenbery D: Deflning apoptosis. Am J Pathol, 146: 16-19, 1995.
28. Kern JA, Slebos RJ, Top B, Rodenhuis S, Lager D, Robinson RA, Weiner D, Schwartz DA: C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin In-vest, 93: 516-520, 1994.
29. Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K: Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer, 27: 1372-1375, 1991.
30. Giatromanolaki A, Gorgoulis V, Chetty R, Koukourakis MI, Whitehouse R, Kittas C, Veslemes M, Gatter KC, Iordanoglou I: C-erbB-2 oncoprotein expression in operable non-small cell lung cancer. Anticancer Res, 16: 987-993, 1996.
31. Pfeiffer P, Clausen PP, Andersen K, Rose C: Lack of prognostic signiflcance of epidermal growth factor receptor and the oncoprotein pl85 HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohisto-chemical study on cryosections. Br J Cancer, 74: 86-91, 1996.